Ningbo Menovo Pharmaceutical Co., Ltd.
Symboli: 603538.SS
SHH
14.81
CNYMarkkinahinta tänään
-164.8178
P/E-suhde
-1.2361
PEG-suhde
3.14B
MRK Cap
- 0.01%
DIV Tuotto
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3108.99 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 961.42 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 1197.96 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 2630.14 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 198.07 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 7254.8 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 7582.87 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 802.34 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 802.34 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 832.39 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 335.17 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 942.78 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 10495.55 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 2040.98 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 2165.58 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 115.34 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 3022.3 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 330.02 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 220.86 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 8.2 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3592.57 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 102.15 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 8956.27 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 72.59 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 853.57 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 4918.84 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 986.88 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1595.49 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 8427.36 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 366.72 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 8794.08 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 17750.35 | - | - | - | |||||||||||||
Total Investments | 1259.87 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 5187.88 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 3040.31 | 846.4 | 410.7 | 838.6 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -17.82 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 90.3 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | -13.64 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 11.27 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | -124.06 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | -98.84 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | -49.56 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 24.33 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 36.58 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -28.65 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0.3 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | -994.74 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 853.67 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | -116.67 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -247.84 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | -399.52 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | -60.49 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 446.21 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 60.68 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -22.05 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | -237.86 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 1234.49 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1472.34 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | -28.65 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | -171.08 | -294.7 | -309.3 | -60.1 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1232.95 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 839.39 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 393.56 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 99.54 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 57.01 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 305.9 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1145.29 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 6.12 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 125.92 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 59.17 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -15.63 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | -27.57 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | -13.31 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | -17.82 | 11.6 | 338.9 | 142.5 |
Usein kysytty kysymys
Mikä on Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) taseen loppusumma?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) kokonaisvarat ovat 4423515920.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on 550731997.000.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.319.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -0.853.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on -0.014.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on -0.013.
Mikä on Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 11585592.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 1302458461.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 291175048.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 351891745.000.